Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$237K Buy
9,855
+584
+6% +$15.3K 0.04% 324
2026
Q1
$260K Buy
9,271
+246
+3% +$6.55K 0.04% 308
2025
Q4
$248K Sell
9,025
-1,163
-11% -$29.3K 0.04% 302
2025
Q3
$248K Buy
10,188
+214
+2% +$5.28K 0.04% 306
2025
Q2
$242K Buy
9,974
+760
+8% +$17.7K 0.05% 285
2025
Q1
$204K Buy
9,214
+1,528
+20% +$40K 0.05% 283
2024
Q4
$206K Sell
7,686
-4,851
-39% -$132K 0.04% 287
2024
Q3
$359K Sell
12,537
-257
-2% -$7.5K 0.09% 177
2024
Q2
$372K Buy
+12,794
New +$352K 0.11% 142
2023
Q4
$249K Buy
+8,654
New +$262K 0.1% 160

Other funds holding PFE

Maia Wealth's PFE Position: Q2 2026 in Review

Maia Wealth increased its Pfizer (PFE) stake by 6.3% in Q2 2026, buying an estimated $15.3K and bringing the position to 9,855 shares worth $237K. The position accounts for 0.04% of the portfolio, ranked #324.

Maia Wealth first reported a position in PFE in Q4 2023 and has held it in 10 quarters since. The position peaked at $372K in Q2 2024. 1,090 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Maia Wealth held 9,855 shares of Pfizer worth $237K as of Q2 2026.
  • Maia Wealth bought 584 Pfizer shares in Q2 2026, an estimated $15.3K.
  • Pfizer made up 0.04% of Maia Wealth's portfolio in Q2 2026, its #324 holding.
  • Maia Wealth first reported a position in Pfizer in Q4 2023 and has held it in 10 quarters since.
  • Maia Wealth's Pfizer position peaked at $372K in Q2 2024.
  • 1,090 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Maia Wealth's 13F filing for Q2 2026, filed 28 Jul 2026.